The Strategic Research Institute is organising a conference on Cardiovascular Drug Discovery & Development from October 20-21, 2003 at Philadelphia, PA. The theme of the conference is to be "Novel Approaches to Atherosclerosis, Hypertension and Thrombosis."
The event would have speakers from the pharma industry presenting relevant and strategically focused information. Some of them are "Role of PPARs in Macrophage Lipid Metabolism and Atherosclerosis" by Chih - Hao Lee, The Salk Institute; "A Novel Approach to Treating Hypertension via Dual Antagonism of AT1 and ETA Receptors in a Single Small Molecule" by John Macor, Bristol - Myers Squibb; "Therapeutic Angiogenesis for the Treatment of Coronary and Peripheral Ischemic Vascular Disease" by Jai Pal Singh, Eli Lilly and Co. Other companies presenting are Aurazyme, Brigham and Women's Hospital, CV Therapeutics, Encysive Pharmaceuticals Inc, GlaxoSmithKline, Isis Pharmaceuticals, NIH/NIAID, University of Pennsylvania Medical Center, UTSouthwestern Medical Center, Trigen, Sangamo Biosciences, Zymogenetics and Zygogen.
The Strategic Research Institute creates conferences which also provide a forum for face-to-face networking between industry leaders, potential strategic partners, prospects and customers.